Podcast: Play in new window | Download | Embed
Subscribe: Apple Podcasts | Spotify | Amazon Music | Android | Pandora | iHeartRadio | Podchaser | Podcast Index | Deezer | RSS
This summer, four new biosimilar drugs became available to U.S. patients and several more are expected to hit the market soon.
Dr. Michael Weinstein interviews Laura D. Wingate, executive vice president, education, support, & advocacy for the Crohn’s & Colitis Foundation about the positive and negative implications of this development for patients.
Continue reading “Episode #48: New Biosimilars Available to Treat IBD (what it means for your patients)”
You must be logged in to post a comment.